Published in Vaccine Weekly, December 21st, 2005
According to researchers in Brazil, "We present our experience with lyophilized Moureau-Rio de Janeiro BCG strain for treatment of patients with recurrent superficial bladder cancer."
"From October 1986 to January 2001, 114 patients were treated by transurethral resection followed by intravesical instillation of BCG at our institution. Follow-up ranged from 10 to 144 months (mean 50.16 months). The treatment included 6 inductions and 10 maintenance cycles of BCG instillations. The patients received an initial dose with 40 mg and subsequent doses with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly